Business Wire

Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals

Zavicefta (ceftazidime-avibactam) is a fixed-dose combination antibacterial that was developed to treat serious Gram-negative bacterial infections. It consists of a combination of avibactam and ...
News Medical

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative ...
Nasdaq

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older - DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today ...
Yahoo Finance

Actavis Up on Positive Phase III Ceftazidime-Avibactam Data

Ceftazidime/avibactam is being developed by Actavis in collaboration with AstraZeneca (AZN) for the treatment of adult hospitalized patients with serious gram-negative bacterial infections including ...
Monthly Prescribing Reference

Ceftazidime/Avibactam Designated QIDP for Gram Negative Infections

Ceftazidime/Avibactam Designated QIDP for Gram Negative Infections The FDA has designated Forest Labs' investigational drug, ceftazidime/avibactam, a Qualified ...
Monthly Prescribing Reference

Ceftazidime-Avibactam Has Potent Activity Against Enterobacteriaceae

PHILADELPHIA, PA—Ceftazidime-avibactam demonstrated “potent activity” against contemporary Enterobacteriaceae (ENT) strains, including those producing prevalent CTX-M-variants, a presentation at ...
FierceBiotech

Actavis Receives U.S. FDA Approval for AVYCAZ™ (CEFTAZIDIME-AVIBACTAM)

DUBLIN, Feb. 25, 2015 -- Actavis plc (NYSE: ACT) today announced the U.S. Food and Drug Administration (FDA) has approved AVYCAZ™ (ceftazidime-avibactam). AVYCAZ was approved for the treatment of ...
Business Wire

Pfizer Launches Zavicefta™ (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria

Avibactam is a first-in-class broad-spectrum β-lactamase inhibitor, which protects ceftazidime against degradation by Class A, C and some D, β-lactamases.Avibactam does not inhibit class B enzymes ...
Medscape

Multidrug-Resistant Infections: What's on the Horizon?

Ceftazidime-avibactam is approved by the US Food and Drug Administration (FDA) for the treatment of complicated intra-abdominal and urinary tract infections, and has activity against ...
FiercePharma

FDA Accepts and Grants Priority Review for AVYCAZ(R) (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)

- Application Seeks to Expand AVYCAZ Label to Include Phase 3 Clinical Data for the Treatment of Complicated Intra-Abdominal Infections (cIAI), in Combination with Metronidazole - DUBLIN, Feb. 24, ...
Medscape

European Commission Clears Antibiotic Zavicefta

The European Commission (EC) has approved the combination antibiotic ceftazidime/avibactam (Zavicefta, AstraZeneca) for the treatment of patients with serious Gram-negative bacterial infections ...
EurekAlert!

Efficacy and safety of ceftazidime-avibactam versus standard antibiotic therapy for resistant Gram-negative bacterial infections: a systematic review and meta-analysis

Background: Drug-resistant Klebsiella pneumoniae infections pose a significant clinical challenge due to limited treatment options. Ceftazidime-avibactam (CAZ-AVI) is a novel β-lactam/β-lactamase ...